XTL Biopharmaceuticals acquires 85% stake in NeuroNOS for autism therapeutics

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to XTL Biopharmaceuticals acquires 85% stake in NeuroNOS for autism therapeutics

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

January 13, 2026 9:28 AM EST

Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher

Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist

FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma

Platform targets the core biology of autism, not just symptomatic relief

Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction share capital

Beyond Air to receive up to... More